Clinical Trial Update: A Two-week Open-label Pharmacodynamic and Pharmacokinetic Study of Multiple Doses of a Darifenacin Liquid Oral Suspension in Children (2 - 15 Years) With Neurogenic Detrusor Overactivity [Phase 2]

View source ↗

Summary

Phase 2 open-label pharmacodynamic/pharmacokinetic study of multiple doses of darifenacin liquid suspension in children with neurogenic detrusor overactivity; t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurogenic Detrusor Overactivity

Drugs mentioned

• Darifenacin (darifenacin)

Snippet

Sponsor: Warner Chilcott | Conditions: Neurogenic Detrusor Overactivity | Phase 2 | Status: TERMINATED | Results posted: 2022-06-09